Durysta actively releases medication for about three to four months, but the pressure-lowering effect typically lasts much longer. In a clinical study, 74% of patients still had reduced eye pressure at the 12-month mark without needing any additional treatment. That gap between when the drug stops releasing and when the benefit fades is one of the most important things to understand about this implant.
Drug Release vs. Pressure-Lowering Effect
Durysta is a tiny biodegradable implant placed inside the eye that slowly releases bimatoprost, the same active ingredient found in common glaucoma eye drops. According to FDA chemistry reviews, the implant releases its medication over roughly three to four months as the polymer material gradually breaks down. After that window, the implant continues to dissolve, but the active drug has largely been delivered.
The pressure-lowering benefit, however, extends well beyond that release period. In a 12-month study of 31 patients who received a single Durysta implant, the average eye pressure reduction at one year was 4.3 mmHg below baseline in patients who didn’t need any additional treatment. That’s a clinically meaningful drop for people with open-angle glaucoma or ocular hypertension. The majority of participants maintained lower pressure for the full year from a single implant.
What Happens After the Effect Fades
About 1 in 4 patients in clinical trials needed additional pressure-lowering treatment (typically eye drops) before the 12-month mark. Your eye doctor will monitor your pressure at regular follow-up visits and can add other treatments if Durysta’s effect wears off sooner than expected.
Here’s the catch: the FDA limits Durysta to a single implant per eye, with no retreatment. This isn’t about the drug wearing off. It’s a safety restriction. Repeat implants have been linked to loss of corneal endothelial cells, the thin layer of cells on the inner surface of your cornea that keeps it clear. In clinical trials, 5 to 10% of patients experienced some degree of this cell loss, and the risk increases with multiple implants. Once those cells are lost, they don’t regenerate. So if your pressure eventually rises again after Durysta, the next step is typically a different treatment rather than a second implant.
Who Can and Can’t Get Durysta
Durysta is approved for people with open-angle glaucoma or ocular hypertension. It’s specifically designed for patients who struggle with daily eye drops, whether due to difficulty administering them, side effects, or simply forgetting doses. A single in-office procedure replaces months of daily drops.
Several conditions rule out Durysta entirely. You cannot receive the implant if you have Fuchs’ dystrophy (a condition that damages corneal endothelial cells), a prior corneal transplant, or an endothelial cell transplant. Your doctor should also use extra caution if you have a limited reserve of corneal endothelial cells, even without a formal diagnosis of dystrophy. Less common corneal complications reported in trials included corneal swelling (1 to 5% of patients) and, rarely, corneal clouding or decompensation.
What the Procedure Costs
The list price for a single Durysta implant starts around $1,986. However, the manufacturer offers a copay assistance program for commercially insured patients that can bring the out-of-pocket cost down to $0 for one implant per eye. Patient assistance programs also exist for uninsured or underinsured individuals. Because Durysta is a one-time treatment per eye, you’re comparing that single cost against the ongoing expense of daily prescription eye drops, which for many patients adds up to a similar amount or more over a year.
What to Watch For After the Implant
The implant is placed during a quick office visit, and most people resume normal activities shortly after. In the weeks and months following, the key things to pay attention to are increasing redness, light sensitivity, pain, or any change in your vision. These could signal a complication like corneal swelling or inflammation and warrant a prompt call to your eye doctor. Routine pressure checks will tell you and your doctor whether the implant is still doing its job or whether it’s time to consider additional treatment.